Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,
Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,
#2188 Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
Introduction: NET are relatively rare and up to still far from fully studied pathology. The frequency of NET GEP does not exceed 2% of all tumors of this localization.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Issaeva S, Khalimova Z, Safarova M, Gumarova A, Yuldashev A,
Keywords: gastroenteropancreatic neuroendocrine tumors, morphology, clinical,
Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Xu J
Authors: Jia R, Li Y, Jin Y, Chen Y, Zhang Y,
Keywords: NEC, checkpoint blockade, anti-PD-1 antibody, NENs,
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Daskalakis K
Authors: Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R,
Keywords: Ex vivo activity, Cytotoxic drugs, Targeted agents, small intestinal neuroendocrine tumors,
Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Lock A
Authors: Lock A, Wirtz R, Kaemmerer D, Haugvik S, Kure E,
Keywords: PREDICT-Study, everolimus, pNEN, gene signature, predictive marker,